The UCSF Children’s Cancer Program offers a wide range of clinical trials for children and young adults with cancer in the San Francisco Bay Area, Northern California, and western United States. We are a designated Children's Oncology Group (COG) Phase 1 center. We also have studies from New Approaches to Neuroblastoma Therapy (NANT), Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL), Sarcoma Alliance for Research Through Collaboration (SARC), pharmaceutical industry, and university institutions. Many of our trials are available for patients up to 30 years of age.
For patients with newly diagnosed cancer, most clinical trials are offered through our participation in the national Children’s Oncology Group. A list of current open trials appropriate for newly diagnosed patients can be found here.
For patients with relapsed or refractory cancer, we strive to provide patients access to the newest treatment options in the form of phase 1 and phase 2 clinical trials. Our current open phase 1 and 2 clinical trials are listed below, according to disease category.
If you are interested in learning more about any of these trials, please contact us at 415-476-3831 or cancerclinicaltrials@peds.ucsf.edu.
ADVL1013: A Phase 1 Study of MK-2206, an AKT inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors or Leukemia
Investigator: Steven DuBois
Status: Open
ADVL1112: A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children with Refractory or Recurrent Solid Tumors and Lymphoma
Investigator: Steven DuBois
Status: Open
ADVL1115: A Phase 1 study of AMG 386 (IND#114215), an Angiopoietin Neutralizing Peptibody, in Children with Relapsed or Refractory Solid Tumors, including CNS Tumors
Investigator: Steven DuBois
Status: Open
Amgen20050252: A Phase I Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors
Investigator: Anuradha Banerjee
Status: Open
PBTC-029: A Phase I and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Investigator: Anuradha Banerjee
Status: Open
Siro topo cyclo: A Phase I Study of Sirolimus in Combination with Oral Cyclophosphamide and Oral Topotecan in Children and Young Adults with Relapsed and Refractory Solid Tumors
Investigator: Steven DuBois
Status: Upcoming
Merck 8669-056: A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
Investigator: Steven DuBois
Status: Open
Merck 8669-062: A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Pediatric Patients with Advanced Solid Tumors
Investigator: Steven DuBois
Status: Open
ACNS0821: Temozolomide with Irinotecan Versus Temozolomide, Irinotecan plus Bevacizumab for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
Investigator: Anuradha Banerjee
Status: Open
ACNS0822: A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab (IND # 7921) and Temozolomide in Newly Diagnosed High Grade Glioma
Investigator: Anuradha Banerjee
Status: Open
ACNS0927: A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)
Investigator: Anuradha Banerjee
Status: Open, in Phase 2
ACNS1021: A Phase II Study of Sunitinib (NSC# 736511, IND# 74019) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Brain Tumors in Pediatric and Young Adult Patients
Investigator: Anuradha Banerjee
Status: Open
ACNS1022: A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytoma and Optic Pathway Gliomas
Investigator: Anuradha Banerjee
Status: Open
ADVL1011: A Phase 1 Study of JAK Inhibition (INCB018424) in Children with Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms
Investigator: Mignon Loh
Status: Open
ADVL0912: A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
Investigator: Steven DuBois
Status: Open
ADVL1013: A Phase 1 Study of MK-2206, an AKT inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors or Leukemia
Investigator: Steven DuBois
Status: Open
ADVL1114: A Phase 1 Study of Temsirolimus (CCI-779, IND#61010) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
Investigator: Steven DuBois
Status: Open
AALL1121: A Single-Arm Multicenter Phase II Study preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
Investigator: Steven DuBois
Status: Open
TACL 2008-002: A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse)
Investigator: Steven DuBois
Status: Open
TACL 2008-004: A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma IND 114301
Investigator: Steven DuBois
Status: Upcoming
TACL 2009-002: Clofarabine with Cytarabine for MRD Positive Leukemia
Investigator: Steven DuBois
Status: Open
TACL 2009-003: A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL
Investigator: Steven DuBois
Status: Open
TACL 2009-004: A Phase I Study of AC220 for Children with Relapsed or Refractory ALL or AML (IND 111461)
*FLT3 inhibitor
Investigator: Steven DuBois
Status: Open
TACL 2009-012: A Phase I Dose Finding Study of Panobinostat In Children with Refractory Hematologic Malignancies
*histone deacetylase (HDAC) inhibitor
Investigator: Steven DuBois
Status: Open
Irino MIBG: High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma
Investigator: Steven DuBois
Status: Open
Siro topo cyclo: A Phase I Study of Sirolimus in Combination with Oral Cyclophosphamide and Oral Topotecan in Children and Young Adults with Relapsed and Refractory Solid Tumors
Investigator: Steven DuBois
Status: Upcoming
NANT 1999-02: Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) (NSC-326321) and Autologous Stem Cell Support For Recurrent High Risk Neuroblastoma
Investigator: Katherine Matthay
Status: Open
NANT 2004-04: A Phase I Study of Fenretinide Lym-X-SorbTM (LXS) Oral Powder in Patients with Recurrent or Resistant Neuroblastoma
Investigator: Katherine Matthay
Status: Open
NANT 2007-02: A Phase I Study Of Bevacizumab With Bolus And Metronomic Cyclophosphamide And Zoledronic Acid In Children With Recurrent Or Refractory Neuroblastoma
Investigator: Katherine Matthay
Status: Open
NANT 2007-03: Vorinostat with 131-I-MIBG Therapy for Resistant/Relapsed Neuroblastoma
Investigator: Steven DuBois
Status: Open
NANT 2008-02: Phase I Study of Vorinostat in Combination with 13-Cis-Retinoic Acid in Patients with Refractory/Recurrent Neuroblastoma
Investigator: Katherine Matthay
Status: Open
NANT 2009-03: Phase I/II Study of MLN8237 in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma (IND# 113644)
Investigator: Steven DuBois
Status: Open
ADVL0912: A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
Investigator: Steven DuBois
Status: Open
ADVL0918: A Phase 1 Study of Temsirolimus in Combination with Irinotecan and Temozolomide in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
Investigator: Steven DuBois
Status: Open
ADVL1011: A Phase 1 Study of JAK Inhibition (INCB018424) in Children with Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms
Investigator: Steven DuBois
Status: Open
ADVL1013: A Phase 1 Study of MK-2206, an AKT inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors or Leukemia
Investigator: Steven DuBois
Status: Open
ADVL1112: A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children with Refractory or Recurrent Solid Tumors and Lymphoma
Investigator: Steven DuBois
Status: Open
ADVL1115: A Phase 1 study of AMG 386 (IND#114215), an Angiopoietin Neutralizing Peptibody, in Children with Relapsed or Refractory Solid Tumors, including CNS Tumors
Investigator: Steven DuBois
Status: Open
Merck 8669-056: A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
Investigator: Steven DuBois
Status: Open
Merck 8669-062: A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Pediatric Patients with Advanced Solid Tumors
Investigator: Steven DuBois
Status: Open
ADVL1014: A Phase I Dose Escalation Study of REOLYSIN, a Replication Competent Reovirus, in Pediatric Patients with Relapsed or Refractory Solid Tumors
Investigator: Steven DuBois
Status: Open
ADVL0911: A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), a Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients with Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors with Neuroendocrine Features
Investigator: Steven DuBois
Status: Open
Siro topo cyclo: A Phase I Study of Sirolimus in Combination with Oral Cyclophosphamide and Oral Topotecan in Children and Young Adults with Relapsed and Refractory Solid Tumors
Investigator: Steven DuBois
Status: Upcoming
Amgen 20050252: A Phase I Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors
*EGFR inhibitor
Investigator: Anuradha Banerjee
Status: Open
ADVL1011: A Phase 1 Study of JAK Inhibition (INCB018424) in Children with Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms
Investigator: Mignon Loh
Status: Open
ADVL0912: A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
Investigator: Steven DuBois
Status: Open
ADVL0918: A Phase 1 Study of Temsirolimus in Combination with Irinotecan and Temozolomide in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
Investigator: Steven DuBois
Status: Open
ADVL1013: A Phase 1 Study of MK-2206, an AKT inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors or Leukemia
Investigator: Steven DuBois
Status: Open
ADVL1014: A Phase I Dose Escalation Study of REOLYSIN, a Replication Competent Reovirus, in Pediatric Patients with Relapsed or Refractory Solid Tumors
Investigator: Steven DuBois
Status: Open
ADVL0911: A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), a Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients with Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors with Neuroendocrine Features
Investigator: Steven DuBois
Status: Open
ADVL1112: A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children with Refractory or Recurrent Solid Tumors and Lymphoma
Investigator: Steven DuBois
Status: Open
ADVL1115: A Phase 1 study of AMG 386 (IND#114215), an Angiopoietin Neutralizing Peptibody, in Children with Relapsed or Refractory Solid Tumors, including CNS Tumors
Investigator: Steven DuBois
Status: Open
ADVL1221: A Phase II Study of Cixutumumab (IMC-A12; IND# 100947) in Combination with Temsirolimus (IND# 61010) in Pediatric Patients with Recurrent or Refractory Solid Tumors
Investigator: Steven DuBois
Status: Open
Merck 8669-056: A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
Investigator: Steven DuBois
Status: Open
Merck 8669-062: A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Pediatric Patients with Advanced Solid Tumors
Investigator: Steven DuBois
Status: Open